Cargando…
Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment
With the huge therapeutic potential, cancer immunotherapy is expected to become the mainstream of cancer treatment. In the current field of cancer immunotherapy, there are mainly five types. Immune checkpoint blockade therapy is one of the most promising directions. Adoptive cell therapy is an impor...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956433/ https://www.ncbi.nlm.nih.gov/pubmed/35340585 http://dx.doi.org/10.1155/2022/8052212 |
_version_ | 1784676568585469952 |
---|---|
author | Yang, Ling Ning, Qian Tang, Sheng-song |
author_facet | Yang, Ling Ning, Qian Tang, Sheng-song |
author_sort | Yang, Ling |
collection | PubMed |
description | With the huge therapeutic potential, cancer immunotherapy is expected to become the mainstream of cancer treatment. In the current field of cancer immunotherapy, there are mainly five types. Immune checkpoint blockade therapy is one of the most promising directions. Adoptive cell therapy is an important component of cancer immunotherapy. The therapy with the cancer vaccine is promising cancer immunotherapy capable of cancer prevention. Cytokine therapy is one of the pillars of cancer immunotherapy. Oncolytic immunotherapy is a promising novel component of cancer immunotherapy, which with significantly lower incidence of serious adverse reactions. The recent positive results of many clinical trials with cancer immunotherapy may herald good clinical prospects. But there are still many challenges in the broad implementation of immunotherapy. Such as the immunotherapy cannot act on all tumors, and it has serious adverse effects including but not limited to nonspecific and autoimmunity inflammation. Here, we center on recent progress made within the last 5 years in cancer immunotherapy. And we discuss the theoretical background, as well as the opportunities and challenges of cancer immunotherapy. |
format | Online Article Text |
id | pubmed-8956433 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-89564332022-03-26 Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment Yang, Ling Ning, Qian Tang, Sheng-song J Immunol Res Review Article With the huge therapeutic potential, cancer immunotherapy is expected to become the mainstream of cancer treatment. In the current field of cancer immunotherapy, there are mainly five types. Immune checkpoint blockade therapy is one of the most promising directions. Adoptive cell therapy is an important component of cancer immunotherapy. The therapy with the cancer vaccine is promising cancer immunotherapy capable of cancer prevention. Cytokine therapy is one of the pillars of cancer immunotherapy. Oncolytic immunotherapy is a promising novel component of cancer immunotherapy, which with significantly lower incidence of serious adverse reactions. The recent positive results of many clinical trials with cancer immunotherapy may herald good clinical prospects. But there are still many challenges in the broad implementation of immunotherapy. Such as the immunotherapy cannot act on all tumors, and it has serious adverse effects including but not limited to nonspecific and autoimmunity inflammation. Here, we center on recent progress made within the last 5 years in cancer immunotherapy. And we discuss the theoretical background, as well as the opportunities and challenges of cancer immunotherapy. Hindawi 2022-03-18 /pmc/articles/PMC8956433/ /pubmed/35340585 http://dx.doi.org/10.1155/2022/8052212 Text en Copyright © 2022 Ling Yang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Yang, Ling Ning, Qian Tang, Sheng-song Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment |
title | Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment |
title_full | Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment |
title_fullStr | Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment |
title_full_unstemmed | Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment |
title_short | Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment |
title_sort | recent advances and next breakthrough in immunotherapy for cancer treatment |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956433/ https://www.ncbi.nlm.nih.gov/pubmed/35340585 http://dx.doi.org/10.1155/2022/8052212 |
work_keys_str_mv | AT yangling recentadvancesandnextbreakthroughinimmunotherapyforcancertreatment AT ningqian recentadvancesandnextbreakthroughinimmunotherapyforcancertreatment AT tangshengsong recentadvancesandnextbreakthroughinimmunotherapyforcancertreatment |